Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy von Ghigo, E., Biller, B. M. K., Colao, A., Kourides, I. A., Rajicic, N., Hutson, R. K., De Marinis, L., Klibanski, A.

Volltext

A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients' modifiable risk factor profile von Benner, J. S., Erhardt, L., Flammer, M., Moller, R. A., Rajicic, N., Changela, K., Yunis, C., Cherry, S. B., Gaciong, Z., Johnson, E. S., Sturkenboom, M. C. J. M., García-Puig, J., Girerd, X.

Volltext

A Four-Year, Open-Label, Multi-Center, Randomized, Two-Arm Study of Genotropin® in Patients with Idiopathic Short Stature: Comparison of an Individualized, Target-Driven Treatment... von Counts, D.R., Silverman, L.A., Geffner, M.E., Rajicic, N., Hey-Hadavi, J., Thornton, P.S., Wajnrajch, M.P.

Volltext

P26 An individualized, target-driven treatment regimen for children with idiopathic short stature (ISS) von Wajnrajch, M.P, Hey-Hadavi, J, Rajicic, N

Volltext

Hepatitis C Virus Prevalence among Patients Infected with Human Immunodeficiency Virus: A Cross-Sectional Analysis of the US Adult AIDS Clinical Trials Group von Sherman, Kenneth E., Rouster, Susan D., Chung, Raymond T., Rajicic, Natasa

Volltext

P02-49 Long-term outcomes of Pegvisomant (Somavert®) monotherapy: Cross-sectional observations from ACROSTUDY von van der Lely, A.J, Brue, T, Buchfelder, M, Ghigo, E, Gomez, R, Hey-Hadavi, J, Lundgren, F, Rajicic, N, Webb, S, Koltowska-Häggström, M

Volltext

Occult hepatitis B in HIV-infected patients von SHIRE, Norah J, ROUSTER, Susan D, RAJICIC, Natasa, SHERMAN, Kenneth E

Volltext

CD4+ T-Cell Restoration After 48 Weeks in the Maraviroc Treatment-Experienced Trials MOTIVATE 1 and 2 von Asmuth, David M, Goodrich, James, Cooper, David A, Haubrich, Richard, Rajicic, Natasa, Hirschel, Bernard, Mayer, Howard, Valdez, Hernan

Volltext

A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS von Marra, Christina M, Rajicic, Natasa, Barker, David E, Cohen, Bruce A, Clifford, David, Donovan Post, M Judith, Ruiz, Armando, Bowen, Brian C, Huang, Meei-Li, Queen-Baker, Jennie, Andersen, Janet, Kelly, Sue, Shriver, Sharon

Volltext

165 Evaluation of Efficacy and Immune Recovery of Optimized Background Therapy (OBT) Plus Maraviroc (MVC) vs Placebo (PBO) in Treatment Experienced (TE) Patients with only R5 HIV-1... von Tressler, R, Goodrich, J, Rajicic, N, Valdez, H, Mayer, H

Volltext

Randomized Phase II Trial of Atovaquone with Pyrimethamine or Sulfadiazine for Treatment of Toxoplasmic Encephalitis in Patients with Acquired Immunodeficiency Syndrome: ACTG 237/A... von Chirgwin, Keith, Hafner, Richard, Leport, Catherine, Remington, Jack, Andersen, Janet, Bosler, Elizabeth M., Roque, Clemente, Rajicic, Natasa, McAuliffe, Vincent, Morlat, Philippe, Jayaweera, D. T., Vilde, Jean-Louis, Luft, Benjamin J.

Volltext

Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials von MOYLE, Graeme, RAJICIC, Natasa, GOODRICH, James, MAYER, Howard, VAIDEZ, Hernan

Volltext

Selective Activation of Peripheral Blood T Cell Subsets by Endotoxin Infusion in Healthy Human Subjects Corresponds to Differential Chemokine Activation von De, Asit K, Miller-Graziano, Carol L, Calvano, Steve E, Laudanski, Krzysztof, Lowry, Stephen F, Moldawer, Lyle L, Remick, Daniel G., Jr, Rajicic, Natasa, Schoenfeld, David, Tompkins, Ronald G

Volltext

Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-bund, multicenter trial von Sattler, FR, Rajicic, N, Mulligan, K, Yarasheski, KE, Koletar, S L, Zolopa, A, Smith, BA, Zackin, R, Bistrian, B

Volltext

Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in South Africa infected with Clade C virus von Eng, S, Sanne, I, Badal-Faesen, S, Wood, R, Rajicic, N, Tressler, R

Volltext

Incidence of infections in treatment-experienced (TE) patients in the MOTIVATE studies of maraviroc (MVC) plus optimized background therapy (OBT) von Ayoub, A, Goodrich, J, Tressler, R, Ryst, E, Rajicic, N, Tomaszewski, K, Mayer, HB

Volltext

O425 Efficacy and safety of maraviroc in treatment-experienced (TE) patients infected with R5 HIV-1: 96-week combined analysis of the MOTIVATE 1 and 2 studies von Hardy, WD, Gulick, R, Mayer, HB, Fätkenheuer, G, Nelson, M, Heera, J, Rajicic, N, Goodrich, J

Volltext

A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients’ modifiable risk factor profile: Novel programme to evaluate/communic... von Benner, J. S., Erhardt, L., Flammer, M., Moller, R. A., Rajicic, N., Changela, K., Yunis, C., Cherry, S. B., Gaciong, Z., Johnson, E. S., Sturkenboom, M. C. J. M., García-Puig, J., Girerd, X.

Volltext

Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection von Fichtenbaum, Carl J., Zackin, Robert, Rajicic, Natasa, Powderly, William G., Wheat, L. Joseph, Zingman, Barry S.

Volltext

Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295 von Fichtenbaum, C J, Zackin, R, Rajicic, N, Powderly, W G, Wheat, L J, Zingman, B S

Volltext